en تخصصي Special پژوهشي Research Article <span style="font-size:12pt"><span style="line-height:16.0pt"><span new="" roman="" style="font-family:" times=""><b><i><span style="font-size:9.0pt">Background & Aims</span></i></b><b><span style="font-size:9.0pt">: </span></b><span style="font-size:9.0pt">Despite the proper understanding of pathophysiological aspects and recent development in therapeutic approaches, the outcome of patients suffering from inflammatory myositis remains unsatisfactory. In addition, there is no clinical information and a clear outlook for this disease in the community. This study aimed to evaluate the outcome of patients with inflammatory myositis (response rate to treatment) and to determine the related and predictive factors of this outcome in these patients.</span></span></span></span><br> <span style="font-size:12pt"><span style="line-height:16.0pt"><span new="" roman="" style="font-family:" times=""><b><i><span style="font-size:9.0pt">Materials & Methods</span></i></b><b><span style="font-size:9.0pt">:</span></b><span style="font-size:9.0pt"> This historical cohort study was performed on 80 patients suffering from inflammatory myositis. By retrospectively reviewing the patient records in the hospital, basic information was extracted and through telephone calls, the outcome status of the disease, and response to treatment were assessed during follow-up and categorized as complete remission, partial remission, and no remission.</span></span></span></span><br> <span style="font-size:12pt"><span style="line-height:16.0pt"><span new="" roman="" style="font-family:" times=""><b><i><span style="font-size:9.0pt">Results</span></i></b><b><span style="font-size:9.0pt">:</span></b><span style="font-size:9.0pt"> Within the follow-up time, 40.0% were completely treated (complete remission), 3.8% had no proper response to treatment (incomplete remission), and 13.8% did not respond to the treatment. Also, 23.8% did not refer for further treatment at least six months from the start of treatment. No death was reported within the follow-up time. We found an association between the quality of treatment response and baseline parameters, including the rate of receiving intravenous immune globulin regimen, time of symptoms onset, gender, different patterns of disease, and disease subtype. </span></span></span></span><br> <span style="font-size:12pt"><span style="line-height:16.0pt"><span new="" roman="" style="font-family:" times=""><b><i><span style="font-size:9.0pt">Conclusion</span></i></b><b><span style="font-size:9.0pt">: </span></b>&nbsp;<span style="font-size:9.0pt">A notable number of inflammatory myositis patients still do not respond to routine treatment, and we, in fact, are at the forefront of managing the disease.</span></span></span></span><span style="font-size:12pt"><span style="line-height:16.0pt"><span new="" roman="" style="font-family:" times=""><span style="font-size:9.0pt"><b> </b></span></span></span></span> Clinical outcome, Inflammatory myositis, Outlook 125 130 http://hsm.umsu.ac.ir/browse.php?a_code=A-10-105-1&slc_lang=en&sid=1 Fatemeh Shirani 10031947532846001537 10031947532846001537 No Department of Internal Medicine, School of Medicine, Hazrat-e Rasool General Hospital, Iran University of Medical Sciences, Tehran, Iran Ali Javadzadeh 10031947532846001538 10031947532846001538 No Department of Internal Medicine, School of Medicine, Hazrat-e Rasool General Hospital, Iran University of Medical Sciences, Tehran, Iran abdolrezahizadiabdo rahaeebakhshizadiabdo abdolrezarahaeebakhshizadiabdo@gmail.com 10031947532846001539 10031947532846001539 Yes Department of Internal Medicine, School of Medicine, Hazrat-e Rasool General Hospital, Iran University of Medical Sciences, Tehran, Iran